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Experimental studies have demonstrated the involvement of angiogenesis-related factors in the pro-
gression of chronic kidney disease (CKD).  There have so far been no reports investigating the distri-
bution and clinical roles of Vasohibin-1 (VASH-1),  a negative feedback regulator of angiogenesis,  in 
CKD.  We recruited 54 Japanese CKD patients and 6 patients who had normal renal tissues excised due 
to localized renal cell carcinoma.  We evaluated the correlations between the renal expression level of 
VASH-1 and the clinical/histological parameters.  VASH-1 was observed in renal endothelial/mesan-
gial cells,  crescentic lesions and interstitial inﬂammatory cells.  Signiﬁcant positive correlations were 
observed between 1) crescent formation and the number of VASH-1+ cells in the glomerulus 
(r＝0.48,  p＝0.001) or cortex (r＝0.64,  p＜0.0001),  2) interstitial cell inﬁltration and the number of 
VASH-1+ cells in the cortex (r＝0.34,  p＝0.02),  3) the glomerular VEGFR-2+ area and the number of 
VASH-1+ cells in the glomerulus (r＝0.44,  p＝0.01) or medulla (r＝0.63,  p＝0.01).  These results suggest 
that the renal levels of VASH-1 may be aﬀected by local inﬂammation,  crescentic lesions and VEGFR-2.
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hronic kidney disease (CKD) is associated with 
an increased risk of end-stage renal disease 
(ESRD) and cardiovascular morbidity and mortality.  
Since the number of patients with ESRD is increasing 
worldwide,  clariﬁcation of the pathological factors 
promoting renal function deterioration and prevention 
of the progression of CKD is required.
　 Glomerulosclerosis and tubulointerstitial altera-
tions are the most common characteristic histological 
alterations observed in patients with renal disorders.  
In general,  deterioration of the renal function corre-
lates better with the degree of tubulointerstitial injury 
than do glomerular alterations [1].  Experimental and 
biopsy studies have shown that the loss of podocytes 
[2-5] and renal capillaries [6] is closely linked with 
the progression of CKD.  Angiogenesis is regulated by 
the balance between proangiogenic and anti-angiogenic 
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factors.  In the normal healthy kidney,  vascular 
endothelial growth factor (VEGF)-A,  a major pro-
angiogenic factor [7],  is primarily expressed by 
podocytes and tubular epithelial cells [8].  VEGF-A 
plays an important role in maintaining the glomerular 
capillary structure and repairing glomerular endothe-
lial cells and peritubular capillaries following injuries 
[6,  9,  10].  Physiological levels of VEGF-A are also 
required for maintenance of the glomerular ﬁltration 
barrier.  In the early stages of diabetic nephropathy,  
the number of glomerular capillaries and the glomeru-
lar levels of VEGF-A and its receptor VEGFR-2 are 
increased [11,  12].  Previous reports have also dem-
onstrated altered distributions of VEGF-A and its 
receptors VEGFR-1 and VEGFR-2 in patients with 
glomerular disorders [13,  14].
　 Vasohibin-1 (VASH-1),  an endogenous angiogene-
sis inhibitor,  was originally identiﬁed in a microarray 
analysis assessing genes up-regulated by VEGF-A in 
endothelial cells [15].  The human VASH-1 protein is 
composed of 365 amino acid residues and regulates the 
proliferation and migration of endothelial cells in an 
autocrine manner; thus it is considered to be a nega-
tive feedback regulator of angiogenesis [15].  A more 
recent report has described the critical role of VASH-1 
in the maintenance of endothelial cells against cellular 
stressors,  and the regulatory mechanisms of its syn-
thesis via posttranscriptional regulation mediated by 
the binding of HuR proteins to AU-rich elements in 
the 3ʼ untranslated region of VASH-1 mRNAs [16].  
VASH-1 does not contain a classic signal sequence;  
rather,  a small vasohibin-binding protein (SVBP) 
serves as its secretory chaperone and contributes to 
its antiangiogenic eﬀects [17].  To date,  no cell sur-
face receptors for VASH-1 have been identiﬁed.  The 
therapeutic eﬃcacy of VASH-1 in experimental models 
of tumors,  atherosclerosis,  proliferative retinopathy 
[15,  18,  19] and diabetic nephropathy [20,  21] has 
been reported.  However,  the renal distribution of 
VASH-1 in patients with CKD has not yet been thor-
oughly examined.
　 In the present study,  we aimed to elucidate the 
renal distribution of VASH-1 in CKD patients.  We 
determined the renal level of VASH-1 by immunohis-
tochemistry and evaluated the correlations between 
the renal VASH-1 level and both clinical and histo-
logical variables,  including angiogenesis-associated 
factors.  This is the ﬁrst study to examine the renal 
distribution of VASH-1 in CKD patients,  and the ﬁrst 
to suggest a potential role for VASH-1 in protecting 
against inﬂammatory and crescentic lesions in patients 
with CKD.
Materials and Methods
　 Study population. We studied 54 Japanese 
CKD patients and their renal biopsy samples.  Normal 
renal tissue samples were also obtained from six 
patients who had undergone surgical excision of dis-
tant portions of the kidneys due to localized renal cell 
carcinoma.
　 All patients attended the Department of Nephrology 
at Okayama University Hospital (Okayama,  Japan) 
between the years 2007 and 2009.  The histological 
evaluations of the biopsies were performed by 2 renal 
pathologists.  To measure the estimated glomerular 
ﬁltration rate (eGFR),  the modiﬁed MDRD equation 
for Japanese individuals [22] was used.  The medical 
records from the day of the renal biopsy were evalu-
ated.  The protocol of the current study was approved 
by the Institutional Ethical Review Board of Okayama 
University Hospital (No. 471,  Oct. 23, 2007),  and 
written informed consent was obtained from all sub-
jects.
　 The patients were followed up annually for three 
years.  We deﬁned a composite renal event as an 
eGFR decline of greater than 30ｵ from baseline,  
initiation of renal replacement therapy or kidney dis-
ease-related death.
　 Histological analysis. Formalin-ﬁxed,  paraf-
ﬁn-embedded sections were stained with periodic acid-
Schiﬀ (PAS),  periodic acid-methenamine-silver (PAM) 
or Massonʼs trichrome for light microscopic observa-
tion.  Renal histological alterations were semiquanti-
tatively evaluated by scoring as follows [23]: for 
mesangial hypercellularity and mesangial sclerosis,  
0＝none,  ＋1＝1-25ｵ,  ＋2＝26-50ｵ,  and ＋3＝51- 
100ｵ of the glomerulus; for interstitial cell inﬁltra-
tion,  interstitial ﬁbrosis and tubular atrophy,  0＝none,  
＋1＝mild,  ＋2＝moderate,  and ＋3＝severe; and for 
vascular sclerosis,  0＝none,  ＋1＝mild,  and ＋2＝
severe.  The mean percentage of glomeruli with cres-
cent formation and global sclerosis was also deter-
mined.  The histological evaluation was performed in a 
blinded fashion by 2 investigators,  and the results 
were averaged.
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　 Immunohistochemistry. Immunohistochemistry 
was performed as previously described [1,  21].  
Following deparaﬃnization and hydration,  formalin-
ﬁxed,  paraﬃn-embedded sections (4-µm-thick) were 
placed in a hot bath in the target retrieval solution,  
pH9.0 (Dako,  Glostrup,  Denmark) at 98℃ for 40min.  
The following primary antibodies were used: (1) 
monoclonal mouse anti-human VASH-1 (2µg/mL) [15];  
(2) monoclonal mouse anti-human CD31 (JC70A; Dako);  
(3) monoclonal mouse anti-human VEGF-A (JH121;  
NeoMarkers,  Fremont,  CA,  USA) [24]; and (4) 
monoclonal mouse anti-human VEGFR-2 (sc-6251;  
Santa Cruz Biotechnology,  Santa Cruz,  CA,  USA) 
[24].  The samples were then washed and the color 
was developed using the EnVision＋ system (Dako) 
according to the manufacturerʼs instructions.  The 
chromogen used was diaminobenzidine.  Sections were 
counterstained with hematoxylin.
　 The mean number of glomerular VASH-1+ cells was 
evaluated as follows: the total number of VASH-1+ 
cells was divided by the number of glomeruli.  The 
number of VASH-1+ cells in the tubulointerstitium in 
the renal cortex and medulla were evaluated as 
follows: the number of VASH-1+ cells was divided by 
the number of observed high power ﬁelds (original 
magnification ×400).  The glomerular CD31+ 
endothelial areas were semiquantitatively evaluated.  
All glomeruli were observed,  and images were ana-
lyzed to determine the mean percentages of the glom-
erular VEGF-A+ and VEGFR-2+ areas.
　 Double immunoﬂuorescent staining was performed 
as previously described [25,  26].  Frozen sections 
were incubated with the following primary antibodies:  
monoclonal mouse anti-human VASH-1 [15],  rat anti-
mouse CD31 (Pharmingen) or polyclonal rabbit anti-α
-smooth muscle actin (α-SMA) (Epitomics,  Burlingame,  
CA,  USA).  For negative control,  we performed 
immunostaining without the usage of primary antibody.  
Subsequently,  the sections were incubated with the 
following secondary antibodies: Alexa Fluor 
546-labeled goat anti-mouse IgG (VASH-1; Invitrogen),  
Alexa Fluor 488-labeled goat anti-rat IgG (CD31;  
Invitrogen) or Alexa Fluor 488-labeled donkey anti-
rabbit IgG (α-SMA; Invitrogen).  The nuclei were 
stained with 4ʼ, 6-diamidino-2-phenylindole (DAPI) 
(Chemicon).  The sections were observed under a 
BIOZERO ﬂuorescent microscope (BZ-800; Keyence,  
Osaka,  Japan) and images were obtained.
　 Statistical analysis. All values are expressed 
as the mean ± standard deviation (SD).  Pearsonʼs 
correlation coeﬃcients were used to evaluate the 
association between 2 continuous variables.  The 
Mann-Whitney U-test was used to compare the expres-
sion levels of VASH-1,  CD31,  VEGF-A and 
VEGFR-2 in the control subjects and patients with 
renal disorders.  Statistical signiﬁcance was deﬁned as 
a p-value of ＜0.05.  The composite renal event rates 
were estimated using the Kaplan-Meier method and 
compared using the log-rank test.  All statistical tests 
were performed using the JMP version 9 software 
package (SAS Institute Inc.,  Cary,  NC,  USA).
Results
　 Characteristics of the CKD patients. The 
mean age of the patients was 45±18 years,  the mean 
eGFR was 75.8±28.1mL/min/1.73m2 and the mean 
daily level of proteinuria was 2.2±4.8g/day.  The 
prevalence of hypertension,  diabetes mellitus and 
dyslipidemia was 34ｵ,  10ｵ and 55ｵ,  respectively 
(Table 1).  The baseline clinical data classiﬁed accord-
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Table 1　 Clinical parameters of the CKD patients
(n＝54)
Age 45±18 (17-82)
Gender (male/female) 22 / 32
BMI (kg/m2) 22.9±3.8 (16.6-31.8)
SBP (mmHg) 126.2±20.4 (82-161)
DBP (mmHg) 76.7±13.6 (49-107)
Hemoglobin (g/dL) 13.2±1.7 (8.5-16.6)
HbA1c (NGSP) (%) 5.8±0.8 (4.8-8.2)
FPG (mg/dL) 107±30 (74-224)
T-cho (mg/dL) 233±86 (106-590)
LDL-C (mg/dL) 139±64 (49-417)
HDL-C (mg/dL) 63±22 (29-132)
TG (mg/dL) 138±74 (42-361)
eGFR (mL/min/1.73m2) 75.8±28.1 (19-132)
Daily proteinuria (g/day) 2.2±4.8 (0.03-30)
Hypertension (%) 34.1
Diabetes mellitus (%) 10.0
Dyslipidemia (%) 54.8
BMI,  body mass index; CKD,  chronic kidney disease; DBP,  dia-
stolic blood pressure; eGFR,  estimated glomerular ﬁltration rate;  
FPG,  fasting plasma glucose; HDL-C,  high-density lipoprotein 
cholesterol; LDL-C,  low-density lipoprotein cholesterol; NGSP,  
national glycohemoglobin standardization program; SBP,  systolic 
blood pressure; T-cho,  total cholesterol; TG,  triglycerides.  The 
values are presented as the means ± SD.  The values in the paren-
thesis are minimum to maximum.
ing to the diagnoses of the renal disorders are shown 
in Table 2.  Only the age,  serum creatinine and eGFR 
were available for the control subjects,  and are shown 
in Table 2.  No signiﬁcant diﬀerences were observed 
among any of the groups.
　 Distribution and number of renal VASH-1+ 
cells in patients with CKD. In the normal con-
trol subjects (Fig.  1,  panels a,  b and c) and the 
patients with mild glomerulonephritis (Fig.  1,  panels 
e and f: IgA nephropathy),  VASH-1+ cells were faintly 
observed in endothelial cells.  However,  VASH-1+ 
cells were not observed in extraglomerular arterioles 
in the normal control subjects (Fig.  1,  panel d).  In the 
patients with purpura nephritis,  VASH-1+ cells were 
observed in cellular crescents and were also distrib-
uted in vasa recta in the renal medulla (Fig.  1,  panels 
g and h).  VASH-1+ cells were also observed in 
endothelial and inﬂammatory cells in the patients with 
granulomatosis with polyangiitis (Fig.  1,  panels i and 
j).  In the patients with diabetic nephropathy,  no 
VASH-1+ cells were observed in the nodular lesions of 
the glomeruli,  although they were observed in inter-
stitial inﬂammatory cells in the cortex (Fig.  1,  panels 
k and l).
　 The number of glomerular VASH-1+ cells was 
signiﬁcantly elevated in the patients with membranous 
nephropathy compared with that observed in the nor-
mal controls and patients with IgA nephropathy and 
diabetic nephropathy (Fig.  2,  panel A).  The numbers 
of VASH-1+ cells in the cortex of patients with mem-
branous nephropathy,  IgA nephropathy,  crescentic 
glomerulonephritis,  lupus nephritis and other condi-
tions were increased compared with those observed in 
the normal controls (Fig.  2,  panel B).  The numbers 
of VASH-1+ cells in the medulla in the patients with 
membranous nephropathy,  IgA nephropathy and cres-
centic glomerulonephritis were also increased com-
pared with those observed in the normal controls 
(Fig.  2,  panel C).
　 Correlations between the number of renal 
VASH-1+ cells and various clinical/histological 
parameters. The numbers of VASH-1+ cells in the 
glomeruli,  cortex and medulla were positively corre-
lated (Fig.  3).  The number of VASH-1+ cells in the 
cortex was inversely correlated with the diastolic 
blood pressure (Table 3).  The number of VASH-1+ 
cells in the medulla was inversely correlated with the 
age and systolic/diastolic blood pressure and posi-
tively correlated with the eGFR.  The renal level of 
VASH-1 did not show a signiﬁcant correlation with 
proteinuria.  The numbers of VASH-1+ cells in the 
glomeruli and cortex positively correlated with the 
presence of crescent formation.  The number of 
VASH-1+ cells in the cortex were positively corre-
lated with the presence of interstitial cell inﬁltration.  
There were no signiﬁcant correlations between the 
numbers of VASH-1+ cells and other clinical parame-
ters (gender,  body mass index,  hemoglobin,  HbA1c,  
fasting plasma glucose,  total cholesterol,  low-density 
lipoprotein cholesterol,  high-density lipoprotein cho-
lesterol and triglycerides) (data not shown).  No other 
histological parameters were signiﬁcantly correlated 
with the levels of VASH-1 (Table 3).
　 Correlations between VASH-1 and the renal 
levels of CD31, VEGF-A and VEGFR-2. Next,  
we investigated the correlations between the renal 
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Table 2　 Characteristics of the patients and controls
n Age(years)
sCr
(mg/dL)
eGFR
(mL/min/1.73m2)
Proteinuria
(g/day)
Number of
glomeruli
Control  6 65±11 0.6±0.3 87.3±18.1 － 20.0±0.0
MN  3 66±9 1.3±0.2 53.5±14.8 4.9±2.5 7.7±3.8
MC  5 37±7 0.7±0.2 88.0±11.4 9.6±1.9 5.4±3.6
Crescentic GN  5 64±7 1.2±0.2 52.1±11.4 0.5±1.9 5.8±3.5
IgA N 18 39±4 0.8±0.1 79.6±6.0 0.6±0.5 7.2±6.9
Lupus N  3 43±9 1.1±0.2 54.7±14.8 1.1±2.5 5.7±4.0
Diabetic N  4 48±8 1.0±0.2 56.7±12.8 3.1±3.0 6.3±3.5
Nephrosclerosis  3 65±9 0.6±0.2 88.2±14.8 0.1±2.5 6.7±7.0
Others 13 39±4 0.8±0.1 86.8±7.1 2.4±1.2 11.9±9.9
eGFR,  estimated glomerular ﬁltration rate; GN,  glomerulonephritis; MC,  minimal change; MN,  membranous nephropathy; N,  nephropathy;  
sCr,  serum creatinine.  The values are expressed as the means ± SD.
levels of VASH-1,  CD31 (a marker for endothelial 
cells),  VEGF-A and VEGFR-2.  The glomerular CD31 
immunoreactivity was specifically localized to 
endothelial cells in the glomerulus and peritubular 
capillaries and arterioles in the normal controls (Fig.  
4,  panel a) and the diseased glomeruli (Fig.  4,  panel 
b-f).  The glomerular CD31 (glomerular endothelial 
area) score tended to be lower in the patients with 
renal disorders than in the normal controls (Fig.  5,  
panel A).  The glomerular CD31 score was not signiﬁ-
cantly correlated with the renal levels of VASH-1 
(Table 4).  Glomerular VEGF-A immunoreactivity was 
primarily localized to podocytes in the normal con-
trols (Fig.  4,  panel g) and was markedly increased in 
the podocytes and additionally observed in glomerular 
endothelial cells (Fig.  4,  panels h-j and l),  crescents 
(Fig.  4,  panel i) and interstitial inﬂammatory cells 
(Fig.  4,  panel k) in the diseased glomeruli.  In tubular 
epithelial cells,  VEGF-A immunoreactivity was slightly 
observed in the normal controls (Fig.  4,  panel g) and 
was markedly increased in the sections of kidney dis-
eases (Fig.  4,  panel h-l).  Recent studies reported 
that VEGF-A was expressed not only in podocytes,  
but also in tubular epithelial cells [13,  14].  The 
glomerular VEGF-A+ areas were signiﬁcantly increased 
in the patients with minimal change disease,  IgA 
nephropathy and other renal disorders compared with 
that observed in the normal controls (Fig.  5,  panel B).  
The presence of glomerular VEGF-A+ areas was not 
correlated with the number of VASH-1+ renal cells 
(Table 4).  Glomerular VEGFR-2+ cells were found in 
endothelial cells and podocytes in the normal controls 
(Fig.  4,  panel m) and were enhanced in the patients 
with renal disorders (Fig.  4,  panels n and p).  Addi-
tionally,  immunoreactivity for VEGFR-2 was observed 
in inﬂammatory cells and crescents (Fig.  4,  panel o 
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Table 3　 Correlations between the renal levels of Vasohibin-1 and the clinical/histological parameters
No. of VASH-1+ cells
in glomeruli
No. of VASH-1+ cells
in cortex
No. of VASH-1+
cells in medulla
r p r p r p
Age (years) 　0.00 0.98 　0.08 0.55 －0.40 0.03a
SBP (mmHg) －0.14 0.37 －0.27 0.09 －0.55 0.02a
DBP (mmHg) －0.15 0.35 －0.34 0.03a －0.52 0.02a
eGFR (mL/min/1.73m2) 　0.12 0.40 －0.15 0.27 　0.39 0.04a
Proteinuria (g/day) 　0.07 0.64 　0.07 0.64 　0.34 0.64
Mesangial hypercellularity 　0.09 0.56 　0.07 0.65 －0.14 0.54
Mesangial sclerosis －0.04 0.79 　0.20 0.20 －0.01 0.96
Crescent formation 　0.48 0.001b 　0.64 ＜0.0001b 　0.22 0.33
Global sclerosis －0.08 0.60 　0.03 0.83 －0.19 0.41
Interstitial cell inﬁltration 　0.20 0.18 　0.35 0.02a －0.06 0.79
Interstitial ﬁbrosis 　0.07 0.67 　0.25 0.10 －0.14 0.92
Tubular atrophy －0.01 0.96 　0.11 0.46 －0.15 0.49
Arteriosclerosis 　0.14 0.39 　0.21 0.17 　0.14 0.55
DBP,  diastolic blood pressure; eGFR,  estimated glomerular ﬁltration rate; No.,  number; SBP,  systolic blood pressure; VASH-1,  
Vasohibin-1.  ap＜0.05.  bp＜0.01.
Table 4　 Correlations between the glomerular CD31+ areas, VEGF+ areas, VEGFR-2+ areas and renal expression of Vasohibin-1
The score of CD31+ area VEGF+ area VEGFR-2+ area
r value p value r value p value r value p value
No. of VASH-1+ cells in glomeruli 　0.04 0.80 　0.01 0.96 0.44 0.01a
No. of VASH-1+ cells in cortex －0.14 0.33 －0.08 0.63 0.25 0.20
No. of VASH-1+ cells in medulla 　0.02 0.93 　0.35 0.14 0.63 0.01a
No.,  number; VASH-1,  Vasohibin-1.  ap＜0.05.  bp＜0.01.
and q) but not in sclerotic areas (Fig.  4,  panel o and 
r).  VEGFR-2 immunoreactivity was moderately observed 
in the tubular epithelial cells in sections of the control 
and the renal disorders (Fig.  4,  panels m-r).  Recent 
study showed similar VEGFR-2 staining pattern in 
tubular epithelial cells [14].  The number of VEGFR-2+ 
areas in the glomeruli was signiﬁcantly increased in 
the patients with minimal change disease compared 
with that observed in the normal controls (Fig.  5,  
panel C).  The number of glomerular VEGFR-2+ areas 
was positively correlated with the numbers of VASH-1+ 
cells in the glomeruli and medulla (Table 4).
　 Double immunostaining for VASH-1, α-SMA 
and CD31. We next performed double immunos-
taining to conﬁrm the localization of VASH-1.  In the 
normal kidney,  endogenous VASH-1 was slightly 
observed in the glomeruli and the peritubular capillar-
ies (Fig.  6,  panels a and g).  Immunoreactivity for 
VASH-1 was increased in the mesangial (α-SMA+) and 
endothelial (CD31+) areas in the patients with lupus 
nephritis (Fig.  6,  panels d-f and j-l) and was also 
increased in the crescents in the patients with IgA 
nephropathy (Fig.  7,  panel a-d).
　 Correlation between the renal levels of 
VASH-1 and renal outcomes. We next per-
formed a Kaplan-Meier analysis to evaluate the poten-
tial clinical usefulness of the renal levels of VASH-1 
in predicting renal outcomes.  The patients were 
stratiﬁed into 2 groups for the Kaplan-Meier analysis,  
with the cutoﬀ values for the renal levels of VASH-1 
being as shown in Fig.  8.  The patients with elevated 
renal levels of VASH-1 tended to experience a higher 
incidence of composite renal events,  but the diﬀerence 
was not statistically signiﬁcant (Fig.  8).
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Fig. 1　 Distribution of Vasohibin-1+ cells in the kidneys.  In the normal control subjects,  VASH-1+ cells were faintly observed in glomeru-
lar endothelial cells (a,  b: arrowheads) and peritubular capillaries in the renal cortex (c: arrowhead).  However,  VASH-1+ cells were not 
observed in extraglomerular arterioles (d).  In the patients with IgA nephropathy,  VASH-1+ cells were faintly observed in glomerular 
endothelial cells (e,  f: arrowheads).  In the patients with purpura nephritis,  VASH-1+ cells were observed in cellular crescents in the 
glomerulus (g: arrowheads) and in the endothelial cells of the vasa recta (h: arrowhead).  In the patients with granulomatosis with poly-
angiitis,  VASH-1+ cells were observed in endothelial and interstitial inﬂammatory cells (i,  j: arrowheads).  In the patients with diabetic 
nephropathy,  no VASH-1+ cells were observed in the nodular lesions of the glomerulus (k: asterisks),  although they were observed in 
inﬂammatory cells in the cortex (l: arrowheads).  VASH-1,  Vasohibin-1.  Scale bars: 200μm (d); 100μm (a,  e,  g,  i,  k and l); 50μm (b,  c,  
f,  h and j).
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Fig. 2　 Renal expression of Vasohibin-1 in patients with various renal disorders.  (A) The glomerular expression of VASH-1 in patients 
with various renal disorders.  (B) The number of VASH-1+ cells in the cortex in patients with various renal disorders.  (C) The number of 
VASH-1+ cells in the medulla in patients with various renal disorders.  ＊p＜0.05 versus normal controls.  #p＜0.05 versus membranous GN.  
GN,  glomerulonephritis ; HPF,  high power field ; MC,  minimal change disease; MN,  membranous nephropathy; N,  
nephropathy; VASH-1,  Vasohibin-1.
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Fig. 3　 Correlations between the numbers of renal Vasohibin-1+ cells.  (A,  B,  C) Correlation between the glomerular,  cortical and 
medullary expressions of VASH-1.  HPF,  high power ﬁeld; VASH-1,  Vasohibin-1.
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Fig. 4　 Immunohistochemistry for CD31,  VEGF-A and VEGFR-2.  Representative photomicrographs of CD31 staining (a-f),  VEGF-A 
staining (g-l) and VEGFR-2 staining (m-r) in the following: the glomeruli of a control subject (a,  g,  m) and patients with IgA nephropathy 
(b,  h,  n),  purpura nephritis (c,  i,  o),  membranous glomerulonephritis (d,  j,  p),  granulomatosis with polyangiitis (e,  k,  q) and diabetic 
nephropathy (f,  l,  r).  The CD31+ glomerular endothelial areas indicate the capillary density of the glomerulus (a-f; arrowheads).  The 
glomerular VEGF-A+ areas were primarily localized to podocytes in the normal controls (g; arrowheads) and were markedly increased in 
podocytes and additionally observed in glomerular endothelial cells (h-j and l; arrowheads),  crescents (i; arrows) and interstitial inﬂam-
matory cells (k; arrows) in the diseased glomeruli.  Glomerular VEGFR-2+ cells were found in endothelial cells and podocytes in the normal 
controls (m; arrowheads) and were enhanced in the patients with renal disorders (n and p; arrowheads).  Additionally,  immunoreactivity for 
VEGFR-2 was observed in inﬂammatory cells and crescents (o and q; arrows),  but not in sclerotic areas (o and r; asterisks).  Scale 
bars: 100μm.
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Fig. 6　 Double immunoﬂuorescent staining for endogenous Vasohibin-1,  CD31 and α-SMA.  Double immunoﬂuorescent staining of 
VASH-1 (red) and α-SMA (green) and merged images in the kidneys in a normal control (a-c) and a patient with lupus nephritis (d-f).  
Although VASH-1 was faintly observed in the normal control glomeruli (a),  increased immunoreactivity for VASH-1 was observed (d) and 
was merged with that of α-SMA in patients with lupus nephritis (f).  Double immunoﬂuorescent staining of VASH-1 (red) and CD31 (green) 
and merged images in the kidneys in a normal control (g-i) and a patient with lupus nephritis (j-l).  VASH-1 was merged with CD31 in the 
patients with lupus nephritis (j-l).  α-SMA,  anti-α-smooth muscle actin; VASH-1,  Vasohibin-1.  Scale bars: 100μm.
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Fig. 7　 Double immunoﬂuorescent staining for endogenous Vasohibin-1,  α-SMA and DAPI in the crescentic lesion.  Double immunoﬂuo-
rescent staining of VASH-1 (red),  α-SMA (green),  DAPI (blue) and merged images in the kidney in a patient with IgA nephropathy (a-h).  In 
the crescentic lesions,  immunoreactivity for VASH-1 was observed and co-localized with α-SMA (a-d).  Panels e-h show the negative 
control staining results for the same glomerulus used in panel a-d.  α-SMA,  anti-α-smooth muscle actin; DAPI,  4ʼ, 6-diamidino-2-
phenylindole; VASH-1,  Vasohibin-1.  Scale bars: 50μm.
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Fig. 5　 Glomerular expressions of CD31,  VEGF-A and VEGFR-2 in patients with 
various renal disorders.  (A) The glomerular expression of CD31 in patients with vari-
ous renal diseases.  †p＜0.05 versus others.  #p＜0.05 versus IgA N.  (B) The glom-
erular expression of VEGF-A in patients with various renal disorders.  ＊p＜0.05 versus 
normal controls.  (C) The glomerular expression of VEGFR-2 in patients with various 
renal diseases.  ＊p＜0.05 versus normal controls.  GN,  glomerulonephritis; MC,  
minimal change disease; MN,  membranous nephropathy; N,  nephropathy.
Discussion
　 Angiogenesis is involved in pathological disorders 
as well as physiological processes [27].  Experimental 
studies have demonstrated the involvement of an 
imbalance in angiogenesis-related factors in the pro-
gression of CKD [11,  28-33] and the potential thera-
peutic eﬀects on CKD achieved by modulating these 
factors [6,  9,  10,  34-39].  The clinical usefulness of 
angiogenesis-associated factors,  such as VEGF-A,  
soluble VEGFR-1/2 and Angiopoietin-1/2,  in CKD 
patients has recently been demonstrated [8,  14,  
40-42].  There are as yet no reports investigating the 
roles of VASH-1 in CKD patients.
　 In the normal kidney,  VASH-1+ cells were faintly 
observed in the glomerular as well as peritubular 
capillary endothelial cells,  and their expression was 
less remarkable than that observed in the CKD 
patients.  In the CKD patients,  VASH-1 was observed 
in the glomeruli and interstitial inﬂammatory cells.  No 
tubular localization of VASH-1 was evident,  excluding 
the possibility of the tubular epithelium as the primary 
source of renal VASH-1.  The numbers of VASH-1+ 
cells in the glomeruli and cortex were positively cor-
related with the presence of crescent formation,  and 
the number of VASH-1+ cells in the cortex was posi-
tively correlated with the presence of interstitial cell 
inﬁltration.  In general,  VASH-1 is involved in the 
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Fig. 8　 Kaplan-Meier analysis of the composite renal endpoint based on the renal levels of Vasohibin-1.  A composite renal event was 
deﬁned as a decline in the eGFR of more than 30% of the baseline value,  initiation of renal replacement therapy or death associated with 
a renal disorder.  In order to perform a Kaplan-Meier analysis of the renal levels of VASH-1,  the patients were stratiﬁed into 2 groups using 
the median as the cutoﬀ point.  The log-rank test was used to compare diﬀerences between the 2 groups.  Increased renal levels of 
VASH-1 tended to be correlated with worse renal outcomes.  HPF,  high power ﬁeld; VASH-1,  Vasohibin-1.
maturation of neovessels,  and the anti-inﬂammatory 
actions of VASH-1 have been observed in experimen-
tal animal models [19-21,  43].  Therefore,  VASH-1 
is thought to be upregulated in interstitial inﬂamma-
tory lesions in a compensatory manner in order to 
stabilize peritubular capillaries and prevent further 
inﬁltration of inﬂammatory cells.  Relevant to the pres-
ent results,  previous reports have demonstrated the 
expression of VASH-1 in monocytes/macrophages in 
association with inﬂammatory lesions [44-47].  Double 
immunoﬂuorescent staining has further revealed that 
VASH-1 is present in glomerular endothelial and 
mesangial cells in patients with renal disorders.
　 Inverse correlations between the number of 
VASH-1+ cells in the medulla and the age/blood pres-
sure and a positive correlation between the number of 
VASH-1+ cells in the medulla and the eGFR were 
observed in CKD patients.  Furthermore,  an inverse 
correlation between the number of VASH-1+ cells in 
the cortex and the diastolic blood pressure was 
observed in CKD patients.  In general,  VASH-1 is 
primarily synthesized and secreted by vascular 
endothelial cells.  These results suggest that the pro-
duction of VASH-1 by vascular endothelial cells is 
reduced in elderly and hypertensive patients due to 
systemic arteriosclerotic alterations accompanied by 
endothelial cell dysfunction,  consistent with recent 
ﬁndings suggesting that VASH-1 is an important fac-
tor for the maintenance of endothelial cells [16].
　 Immunoreactivity for VASH-1 was not observed in 
the sclerotic area of glomeruli.  Because VASH-1 has 
been shown to ameliorate the accumulation of matrix 
proteins in the mesangial area in animal models of 
diabetic nephropathy,  we expected to observe increased 
immunostaining for VASH-1 in the nodular and diﬀuse 
lesions of our patients with diabetic nephropathy.  Our 
ﬁndings indicate that VASH-1 may be expressed in 
endothelial and mesangial cells at a relatively earlier 
stage of disease progression,  rather than at the later 
stage accompanied by sclerotic lesions.
　 A recent report demonstrated that VASH-1 is 
primarily expressed in the cytoplasm and membrane of 
renal tubular epithelial cells and partly in vascular 
endothelial cells and glomerular mesangial cells [48].  
This discrepancy may be attributable to the use of 
distinct anti-VASH-1 antibodies.  In most reports 
examining the VASH-1 expression in human tissues 
[19,  24,  46,  49-51],  including the present study,  a 
murine monoclonal antibody against a synthetic peptide 
corresponding to the 286-299 amino acid sequence of 
VASH-1 [15] was used.  However,  distinct anti-VASH-1 
antibodies were used in the above-described report 
[48],  partly explaining the discrepant ﬁndings.
　 VASH-1 was originally identiﬁed as a gene that was 
up-regulated by VEGF-A in endothelial cells [11].  
Therefore,  we next aimed to investigate the correla-
tion between VEGF-A/VEGFR-2 and the VASH-1 
levels in the kidney.  In the present study,  no signiﬁ-
cant correlations between the glomerular VEGF-A 
level and the VASH-1 levels were observed.  A recent 
report indicated that in cancer-associated endothelial 
cells,  the increase in endothelial EZH2,  a member of 
the polycomb-group (PcG) proteins,  is a direct result 
of VEGF-A stimulation by a paracrine circuit that 
promotes angiogenesis by methylating and silencing 
VASH-1 [52].  The levels of VASH-1 observed in CKD 
patients may be aﬀected by several pathways down-
stream of VEGF-A stimulation,  and may therefore be 
partly attributable to the posttranscriptional regula-
tion mediated via the HuR induced by oxidative stress,  
as recently demonstrated by Miyashita et al.  [16].
　 The expression of VASH-1 was not signiﬁcantly 
correlated with the presence of CD31+ glomerular 
endothelial areas or chronic lesions (mesangial sclero-
sis,  global sclerosis,  interstitial ﬁbrosis,  tubular 
atrophy and arteriosclerosis),  although it was posi-
tively correlated with the presence of crescent forma-
tion,  interstitial cell inﬁltration and VEGFR-2+ areas 
in the glomeruli and medulla.  These results suggest 
that the renal levels of VASH-1 may be aﬀected by the 
status,  but not the number of endothelial cells.  
Similarly,  previous reports have demonstrated a 
positive correlation between the levels of VASH-1 and 
VEGFR-2 in tumors and ocular lesions [24,  46,  49,  
53,  54].  On the other hand,  crosstalk between the 
glomerular endothelial cells and podocytes is crucial 
for the maintenance of the glomerular architecture,  as 
well as the glomerular ﬁltration barrier.  The involve-
ment of the VEGF-A/VEGFR-2 system in this regu-
latory mechanism has been extensively studied to date 
[55].  VASH-1 may be regulated downstream of 
VEGFR-2 signaling in endothelial cells,  and then may 
indirectly aﬀect podocytes,  inﬂammatory cells and 
mesangial cells in association with its potential reno-
protective role.  We previously demonstrated a reno-
protective role of VASH-1 via its direct eﬀects on 
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glomerular endothelial and mesangial cells and podo-
cytes,  and showed that this renoprotection was due to 
various mechanisms in both experimental animal mod-
els and cell cultures.  Therefore,  direct protective 
eﬀects of endogenous VASH-1 on renal component 
cells may also play a role in suppressing the progres-
sion of CKD.
　 The Kaplan-Meier analysis further indicated that 
elevated renal levels of VASH-1 at baseline tended to 
predict a poor renal outcome,  although the diﬀerences 
in the data did not reach statistical signiﬁcance.  
Studies employing a larger number of patients both in 
total and in each disease category may lead to the 
identiﬁcation of a signiﬁcant diﬀerence in the future.  
Elevated expressions of VASH-1 have been reported 
to predict worse clinical outcomes in patients with 
various cancers,  which are similar to the ﬁndings in 
the present study [24,  46,  49-51,  56].  In various 
animal disease models,  including those of tumors and 
diabetic nephropathy,  the injection of adenoviral vec-
tor encoding VASH-1 results in therapeutic eﬀects 
[15,  19-21,  43,  57-59].  More recent ﬁndings have 
demonstrated the role of VASH-1 in enhancing the 
stress resistance of endothelial cells [16].  Therefore,  
we conjecture that endogenous VASH-1 is upregu-
lated in response to increased disease activity and 
endothelial cell stress in a compensatory manner in 
patients with renal disorders.
　 Our study had several limitations.  The sample size 
was not adequate for making comparisons between the 
patients with various renal disorders.  In addition,  the 
mechanisms underlying the relationships among the 
renal expression of VASH-1,  inﬂammatory stimuli and 
VEGFR-2 were not fully clariﬁed.  To further eluci-
date these precise mechanisms,  basic research on 
VASH-1 in vitro and in vivo,  including studies using 
animal models of renal disorders,  is required.
　 In conclusion,  we investigated the renal distribu-
tion of VASH-1 in patients with CKD for the ﬁrst 
time,  and demonstrated an association between the 
renal VASH-1 levels and renal histological altera-
tions,  such as inﬂammation and crescent formation,  as 
well as the VEGFR-2 levels,  thus suggesting a poten-
tial renoprotective role for VASH-1 in response to 
various stresses in patients with CKD.
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